Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress
Q4 2024 Management View CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion ...
Business Insider29d
Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00. Akash Tewari’s rating is based on a combination of factors ...
Seeking Alpha8d
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress
Key drivers include expanding Cabo’s indications and advancing Zanza pivotal trials. The Cabo franchise delivered strong growth, with Q4 U.S. net product revenues of $515 million, representing a ...